Lorlatinib for first-line treatment of ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced lung cancer (stage IIIB/C or IV) that is ALK-positive, confirmed by a specific test.
- You must not have had any prior cancer treatment for advanced disease, including chemotherapy, targeted therapy, or immunotherapy.
- You must have at least one measurable tumor outside the brain, not previously irradiated.
- You must be 18 years or older and have good organ function (bone marrow, pancreas, kidneys, liver).
- You must be willing to provide a tumor tissue sample (if not already available, a new biopsy is needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
This trial tests adding cholesterol-lowering drugs to manage high cholesterol caused by lorlatinib, a targeted therapy for advanced ALK-positive non-small cell lung cancer. It aims to help patients stay on lorlatinib safely while controlling their cholesterol levels.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.